5 Practical Uses for OCT-A in AMD and Diabetic Retinopathy
Optical coherence tomography angiography (OCT-A) can be a useful adjunct in retina practices with or without fluorescein angiography. Here are five uses for the imaging technology in managing age-related macular degeneration (AMD) and diabetic retinopathy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
“I don’t think that OCT-A will replace fluorescein angiography (FA) anytime soon, especially in my uveitis practice, but I think it can be a useful adjunct in clinical practice,” says Danny Mammo, MD, a vitreoretinal disease and uveitis specialist at Cleveland Clinic Cole Eye Institute.
Dr. Mammo presented on practical uses for OCT-A at the 2023 Cole Eye Institute Retina Summit in New Orleans, a prelude to the 2023 Association for Research in Vision and Ophthalmology (ARVO) annual meeting.
“OCT-A can improve detection of choroidal neovascularization (CNV), specifically type 1, where sensitivity is close to 100%,” he says.
OCT-A identifies retinal and choroidal vessels by detecting the motion of red blood cells. En face images of vascular networks can be correlated with B-scan images to pinpoint location and flow. B-scan images can be segmented to display en face images of the different layers:
Superficial retinal plexus
Deep retinal plexus (which along with the superficial retinal plexus can reveal retinal vascular disease)
Outer retina (which normally is avascular and, therefore, can reveal choroidal neovascular disease)
Choriocapillaris (which can reveal choroidal vascular disease)
Outer retina to choriocapillaris (ORCC) slabs combine views of the outer retina and choriocapillaris, which is especially helpful for identifying choroidal neovascular membranes.
While OCT-A requires high-speed instruments and longer processing times, the technology provides 3D images of the deep retina and choroid not visible by FA. In addition, OCT-A does not rely on dye injection.
“We’ve had two shortages of fluorescein in the past few years — one during the COVID-19 pandemic and one when a manufacturer stopped producing the dye,” says Dr. Mammo. “Also, satellite clinics don’t always have FA available, so it makes sense for retina specialists to get comfortable using OCT-A to help manage patients.”
In his clinic, Dr. Mammo uses OCT-A when evaluating and managing patients referred for age-related macular degeneration (AMD) or diabetic retinopathy. Here he shares some practical uses of the imaging technology.
Use 1: Detecting choroidal neovascular membranes
OCT-A can help retina specialists determine if an exudative choroidal neovascular membrane (CNVM) is present. It can help them examine pigment epithelial detachments (PEDs) and recognize broad, low-lying PEDs.
In one example shared by Dr. Mammo, a 74-year-old patient with a history of dry AMD in the right eye and wet AMD in the left eye presented with new metamorphopsia of the right eye. OCT (compared with an OCT six weeks earlier) demonstrated a larger PED with overlying subretinal hyper-reflective material (SHRM).
On a segmented ORCC slab, red flow within the PED suggested that the overlying SHRM was likely an active CNVM — even though subretinal or intraretinal fluid was not evident.
“You have to be careful when looking at OCT-A,” says Dr. Mammo. “Just like FA can have some questionable areas (Is it leakage or not?), there easily can be segmentation errors in OCT-A of patients with large PEDs. Large areas of geographic atrophy can mimic membranes. They can fool you into thinking that you’re seeing membranes when it’s really just underlying choroidal vessels appearing in the superficial slabs.”
Risk stratifying patients with dry AMD will become more relevant as more dry AMD therapies become widely available.
“Can complement-inhibitor drugs potentially cause a CNVM? Some are concerned about that risk,” says Dr. Mammo. “OCT-A may be helpful in learning if having a net [a network of neovascular vessels] increases risk for CNVM or if, as some have reported, nets actually slow down adjacent or overlying geographic atrophy.”
One study has reported that patients with wet AMD in one eye had a 6%-27% chance of having a nonexudative net in the fellow eye. Over time, the incidence of exudation in these eyes was 20%-80%.
Another study, which characterized nuanced exudation in patients receiving pegcetacoplan, reported that new-onset exudative AMD in the study eye was associated with baseline exudative AMD in the contralateral eye as expected, but also a double-layer sign, suggestive of a nonexudative macular neovascularization lesion in the study eye.
“In this study, a double-layer sign was suggestive of a nonexudative net but was not confirmed with OCT-A,” notes Dr. Mammo. “We need to look at the OCT-As of these patients to see if they can help guide us in stratifying these patients for AMD treatment.”
Use 3: Assessing CNVM in non-AMD conditions
There are other diseases that can present with subretinal fluid and cavitary lesions of the retina with or without CNVM.
“OCT-A can be instrumental in deciding whether to treat or observe these lesions,” says Dr. Mammo.
For example, one patient referred for central serous retinopathy had OCT-A imaging that revealed something else on the ORCC slab: green flow within the PED. The imaging confirmed that instead of just subretinal fluid due to central serous retinopathy, the patient had a CNVM.
Another patient, a 44-year-old with macular telangiectasia, presented with new vision changes. The ORCC slab revealed flow in a new subretinal lesion with a net. He was treated, and his CNVM resolved.
Use 4: Raising suspicion for a non-AMD disease
“One of my favorite things to do when I am referred AMD patients is to diagnose something other than AMD,” says Dr. Mammo.
OCT-A can help diagnose these other diseases.
A 71-year-old male was referred to Dr. Mammo for 20/40, 20/50 vision. Imaging was unremarkable. Only mild drusen appeared on the OCT. On OCT-A, the superficial and deep retinal slabs appeared normal. However, the choriocapillaris slab showed flow voids in both eyes.
The patient was sent to a location with indocyanine green angiography, which revealed a dense hypofluorescent lesion in the macula of each eye. This patient was diagnosed with persistent placoid maculopathy and now is treated with immunosuppression.
Use 5: Assessing ischemia and neovascularization in diabetic retinopathy
In patients with diabetic retinopathy, retina specialists care most about three things, according to Dr. Mammo:
Presence of diabetic macular edema
Presence of neovascularization
“All of these factors affect your treatment recommendation,” he says. “OCT-A can help you evaluate these three things and make clinical decisions very quickly.”
For example, a 53-year-old man with well-controlled proliferative diabetic retinopathy presented with visual acuity of 20/80 in the right eye and 20/50 in the left eye. He claimed to have well-managed hemoglobin A1c and couldn’t understand why his vision was poor.
OCT-A produced clear images of enlarged foveal avascular zones that were affecting the patient’s vision. Despite adequate treatment of his diabetic macular edema and currently good control of his hemoglobin A1c, the patient was able to clearly see the impact of ischemia on his central vision when compared with a normal image.
“In situations like this, OCT-A can be a great teaching tool for patients,” says Dr. Mammo.
For example, a 30-year-old woman with proliferative diabetic retinopathy in both eyes deferred fluorescein testing due to pregnancy. OCT-A, especially with the wider 12 mm or 15 mm scans, was effective at showing severe ischemic burden.
Vitreoretinal interface slabs, while not clear, indicated possible lesions in her right and left eyes. By comparing the B-scan images, red flow revealed the presence of neovascular lesions in two instances, while lack of flow and improper segmented lines indicated segmentation error in a third instance. (See slideshow, below.)